Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
6.49
+0.29 (4.68%)
Aug 13, 2025, 4:00 PM - Market closed
Kura Oncology Employees
Kura Oncology had 192 employees as of December 31, 2024. The number of employees increased by 50 or 35.21% compared to the previous year.
Employees
192
Change (1Y)
50
Growth (1Y)
35.21%
Revenue / Employee
$433,745
Profits / Employee
-$1,026,938
Market Cap
563.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KURA News
- 4 days ago - Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Kura Oncology Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 10 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Kura Oncology to Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well - Seeking Alpha
- 2 months ago - Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - GlobeNewsWire
- 2 months ago - Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML - GlobeNewsWire